EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States

Amar Krishnaswamy, Amr E Abbas, Vasilis C Babaliaros, Adam B Greenbaum, Pradeep Yadav, Issam D Moussa, Grant W Reed, Roger J Laham, Michael A Morse, Evelio Rodriguez, Jeremiah P Depta, James M McCabe und 4 weitere

JACC: Cardiovascular Interventions · 2025

DOI: 10.1016/j.jcin.2025.06.039 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Amar Krishnaswamy und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: krishna2@ccf.org. Hauptthemen laut MEDLINE: Aortic Valve, Aortic Valve Stenosis, Balloon Valvuloplasty, Heart Valve Prosthesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up. OBJECTIVES: The aim of this study was to analyze the outcomes of AViV therapy using contemporary balloon-expandable valves (BEVs) in a large series with mid-term outcomes. METHODS: BEV AViV patients (June 2015 to December 2023) in the Society for Thoracic Surgeons (STS)/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were propensity matched to native transcatheter aortic valve replacement (TAVR) patients. Primary analysis included death and stroke at 5 years. Comparisons were also made on the basis of STS score, BEV subtype, and stented vs stentless index surgical valve type. RESULTS: In total, 14,474 AViV patients were matched to 385,556 TAVR patients (13,638 pairs). The mean age was 74 years, and the mean STS Predicted Risk of Mortality was 6.1%. Emergency cardiac surgery (0.2%) and bioprosthetic valve fracture (22%) were infrequent. Death (43.1% vs 55.2%; P < 0.001), stroke (10.5% vs 11.8%; P < 0.001), and their composite were lower for AViV compared with TAVR at 5 years with similar findings at each STS tertile. The SAPIEN 3 Ultra RESILIA device demonstrated lower discharge echo gradients for all sizes (20 mm, 19.4 mm Hg vs 23.8 mm Hg; 23 mm, 15.1 mm Hg vs 19.2 mm Hg; 26 mm, 12.1 mm Hg vs 15.1 mm Hg; and 29 mm, 8.6 mm Hg vs 12.1 mm Hg). There was no difference in death or stroke at 5 years for stentless vs stented surgical valves (42.9% vs 46.0%; P = 0.12). CONCLUSIONS: This large, real-world analysis confirms the safety and durability of AViV compared with TAVR at all surgical risk levels at mid-term follow-up. Consideration may be given to broadening the indication for AViV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic ValveAortic Valve StenosisBalloon ValvuloplastyHeart Valve ProsthesisHeart Valve Prosthesis ImplantationTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleProsthesis DesignProsthesis FailureRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeUnited States

Stichwörter der Autor:innen

aortic valve-in-valvebioprosthesissurgical valvetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: krishna2@ccf.org.
  • Department of Cardiovascular Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
  • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Piedmont Heart Institute, Atlanta, Georgia, USA.
  • Carle Heart and Vascular Institute, University of Illinois, Champaign, Illinois, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.

Förderung

  • Edwards Lifesciences Corporation

Zitieren

APA

Krishnaswamy, A., Abbas, A. E., Babaliaros, V. C., Greenbaum, A. B., Yadav, P., Moussa, I. D., Reed, G. W., Laham, R. J., Morse, M. A., Rodriguez, E., Depta, J. P., McCabe, J. M., Bapat, V. N., Thourani, V. H., Kapadia, S. R., & Kaneko, T. (2025). Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.06.039

Vancouver

Krishnaswamy A, Abbas AE, Babaliaros VC, Greenbaum AB, Yadav P, Moussa ID, et al. Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.06.039

BibTeX
@article{Krishnaswamy2025,
  author = {Krishnaswamy, Amar and Abbas, Amr E and Babaliaros, Vasilis C and Greenbaum, Adam B and Yadav, Pradeep and Moussa, Issam D and Reed, Grant W and Laham, Roger J and Morse, Michael A and Rodriguez, Evelio and Depta, Jeremiah P and McCabe, James M and Bapat, Vinayak N and Thourani, Vinod H and Kapadia, Samir R and Kaneko, Tsuyoshi},
  title = {Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1016/j.jcin.2025.06.039}
}
Kostenlos starten →